Swiss GDP contracted by 0.5% in the third quarter, according to final figures released on Friday. This result was slightly below the expected 0.4% contraction, marking the first negative growth since the start of the year.
US tariffs, which rose to 39% in August, were a key factor affecting the economy. Most major trading partners faced lower tariffs, impacting net exports and leading to a decrease in growth for the quarter. A preliminary agreement to reduce tariffs may result in improved figures soon.
Long Term Economic Challenges
The Swiss economy’s reliance on the pharmaceutical sector presents potential long-term challenges. Since 2014, growth in this sector has outpaced other industries, skewing overall economic performance. US efforts to shift pharmaceutical production domestically could affect Swiss growth, as companies have begun investing in the US.
In the short term, the Swiss economy is expected to recover from the third-quarter contraction once tariffs are reduced. The Swiss Franc gained slightly against the euro, reflecting these economic dynamics and anticipated future growth improvements.
The Swiss economy’s 0.5% contraction in the third quarter of 2025 was a direct result of temporary US tariffs, not a fundamental breakdown. We saw net exports drag down growth after a period of front-loading in the first half of the year. With a preliminary trade deal now in place and tariffs being reduced, we should look past this backward-looking data point.
This tariff-induced slump is likely to reverse sharply in the coming months, creating a short-term tailwind for the Swiss Franc. Recent data already supports this, with the latest Swiss PMI reading for November 2025 jumping to 53.1, firmly back in expansionary territory after dipping in August and September. We should anticipate that upcoming Q4 export and industrial production figures will confirm this rebound.
Impact of Pharmaceutical Sector Dependency
For derivative traders, this points to near-term strength in the CHF, particularly against the euro. Buying short-dated call options on the CHF expiring in early 2026 could capture this expected bounce in economic activity. Implied volatility may also decrease as the tariff uncertainty fades, potentially making option strategies more attractive.
However, a more significant issue is Switzerland’s growing over-reliance on its pharmaceutical sector for economic growth. This dependency has become much more pronounced since the mid-2010s, masking weaker performance in other industries. This concentration risk is the key long-term factor to watch for the Swiss economy.
The US administration’s push to onshore production poses a direct threat to this vital Swiss industry. We are already seeing large Swiss pharmaceutical firms, such as Roche, announcing major new investments in US-based manufacturing facilities. These are funds and jobs that are not being invested back into Switzerland.
This creates a clear divergence between the short-term positive outlook and a more problematic long-term picture. While the economy will likely rebound from the Q3 2025 contraction, the structural headwinds from the pharma sector are gathering strength. This suggests that any CHF rally in the coming weeks might be a good opportunity to position for longer-term weakness using strategies like calendar spreads.
